{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:49:40Z","timestamp":1793047780456,"version":"4.5.0"},"reference-count":54,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Psilocybin has been proposed as a rapid-acting antidepressant (onset &amp;lt;2 weeks) with sustained effects (&amp;gt;6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind, placebo-controlled randomized clinical trial of participants diagnosed with moderate to severe recurrent MDD was conducted at the Northern Stockholm Psychiatric Clinic between January 26, 2021, and February 19, 2024. Statistical analysis was performed from February 20, 2024, to June 20, 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants received a single dose of psilocybin (25 mg) or active placebo (niacin, 100 mg) and 5 psychotherapeutic support sessions during 17 days.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was between-group difference in change in Montgomery-\u00c5sberg Depression Rating Scale (MADRS) score from baseline to day 8. Secondary end points included MADRS scores on days 15, 42, and 365, as well as monthly self-reports (MADRS-S) of depressive symptoms, disability, quality of life, and anxiety throughout the 365-day follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The study included 35 participants (21 [60%] female; mean [SD] age, 41.0 [10.1] years) diagnosed with moderate to severe recurrent MDD, with 17 randomized to the psilocybin group and 18 to the niacin group. The study met its primary end point with a significant mean between-group difference (model estimated) in change in MADRS score on day 8 (\u22127.27; 95% CI, \u221212.89 to \u22121.65;\n P<\/jats:italic>\n \u2009=\u2009.01) in favor of psilocybin. The between-group difference was significant also on days 15 (mean difference, \u221211.03; 95% CI, \u221216.65 to \u22125.42;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and 42 (mean difference, \u22128.33; \u221213.94 to \u22122.71;\n P<\/jats:italic>\n \u2009=\u2009.004) but no longer on day 365 (mean difference, \u22123.68; \u22129.30 to 1.94;\n P<\/jats:italic>\n \u2009=\u2009.20). For MADRS-S, the psilocybin group had a significantly greater reduction beginning at day 2 (mean difference, \u22129.58; 95% CI, \u221216.05 to \u22123.11;\n P<\/jats:italic>\n \u2009=\u2009.004), with group differences persisting through day 102 (mean difference, \u22126.60; 95% CI, \u221213.01 to \u22120.19;\n P<\/jats:italic>\n \u2009=\u2009.04) and then isolated effects at days 283 and 343. Most reported treatment-emergent adverse events were transient and of mild to moderate severity. No drug-related serious adverse events were reported. Two participants in the psilocybin group reported persistent, severe anxiety that required medical attention.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of MDD, a single dose of psilocybin was associated with rapid antidepressant effects, observed by day 2 and persisting for more than 3 months on secondary outcomes; psilocybin was generally well tolerated, but some individuals required additional support after dosing due to anxiety. These results suggest that psilocybin may provide a rapid and relatively long-lasting antidepressant effect on major depressive disorder, warranting further investigation into repeated dosing or adjunctive treatment strategies.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04630964<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.12589","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:30:30Z","timestamp":1778859030000},"page":"e2612589","source":"Crossref","is-referenced-by-count":7,"title":["Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression"],"prefix":"10.1001","volume":"9","author":[{"given":"Hampus","family":"Yngwe","sequence":"first","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Plav\u00e9n-Sigray","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"},{"name":"Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Johan","family":"Ekman","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Henje","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Berglund","sequence":"additional","affiliation":[{"name":"Epistat AB, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Tiger","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beckman","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"zoi260379r1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","article-title":"Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study.","volume":"126","author":"Liu","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"11","key":"zoi260379r2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"11","key":"zoi260379r3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00228-023-03559-4","article-title":"Prevalence, trends, and individual patterns of long-term antidepressant medication use in the adult Swiss general population.","volume":"79","author":"Amrein","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"zoi260379r4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response: understanding and managing antidepressant side effects.","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"issue":"2","key":"zoi260379r5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/02698811231224171","article-title":"What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: a systematic review.","volume":"38","author":"Niarchou","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"4","key":"zoi260379r6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"issue":"2","key":"zoi260379r7","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics.","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr Biol"},{"key":"zoi260379r8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J Affect Disord"},{"issue":"5","key":"zoi260379r9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi260379r10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study.","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"zoi260379r11","doi-asserted-by":"publisher","author":"Metaxa","journal-title":"BMJ","DOI":"10.1136\/bmj-2023-078084"},{"issue":"12","key":"zoi260379r12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi260379r13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15449","article-title":"Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder.","volume":"86","author":"Goodwin","year":"2025","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"zoi260379r14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.","volume":"37","author":"Sloshower","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"12","key":"zoi260379r15","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"12","key":"zoi260379r16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"0","key":"zoi260379r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.","volume":"76","author":"Erritzoe","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"zoi260379r18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up.","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"2","key":"zoi260379r19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"zoi260379r20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/17512433.2023.2279736","article-title":"Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis.","volume":"16","author":"Muthukumaraswamy","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"zoi260379r21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials.","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10378","key":"zoi260379r22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0140-6736(23)00264-7","article-title":"The therapeutic potential of psychedelics: the European regulatory perspective.","volume":"401","author":"Butlen-Ducuing","year":"2023","journal-title":"Lancet"},{"issue":"7650","key":"zoi260379r23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"zoi260379r24","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.8-6-579","author":"Rawlins","year":"2008","journal-title":"Clin Med (Lond)"},{"issue":"12","key":"zoi260379r25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"10","key":"zoi260379r26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"20","key":"zoi260379r27","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"zoi260379r29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"zoi260379r30","author":"Sheehan","journal-title":"J Clin Psychiatry"},{"key":"zoi260379r32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability.","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"zoi260379r33","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"10","key":"zoi260379r34","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"7","key":"zoi260379r35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"zoi260379r36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.","volume":"143","author":"Turkoz","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"zoi260379r37","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial.","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"zoi260379r38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis.","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"zoi260379r39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4088\/JCP.v65n0406","article-title":"Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report.","volume":"65","author":"Husain","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"10128","key":"zoi260379r40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"zoi260379r41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/archpsyc.62.4.409","article-title":"Cognitive therapy vs medications in the treatment of moderate to severe depression.","volume":"62","author":"DeRubeis","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"zoi260379r42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamapsychiatry.2016.3644","article-title":"Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis.","volume":"74","author":"Brunoni","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi260379r43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archgenpsychiatry.2011.2044","article-title":"Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.","volume":"69","author":"Gibbons","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"14","key":"zoi260379r45","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing.","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"zoi260379r46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis.","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260379r47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12888-016-0851-4","article-title":"Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients.","volume":"16","author":"Seem\u00fcller","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"1","key":"zoi260379r48","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15449","article-title":"Results from a long-term observational follow-up study of a single dose of psilocybin for a treatment-resistant episode of major depressive disorder.","volume":"86","author":"Goodwin","year":"2025","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"zoi260379r49","first-page":"1","article-title":"Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials.","volume":"16","author":"Health Quality Ontario","year":"2016","journal-title":"Ont Health Technol Assess Ser"},{"issue":"18","key":"zoi260379r50","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260379r51","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1017\/S0033291712001882","article-title":"A randomized, prospective pilot study of patient expectancy and antidepressant outcome.","volume":"43","author":"Rutherford","year":"2013","journal-title":"Psychol Med"},{"issue":"3","key":"zoi260379r52","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10591-012-9201-y","article-title":"A literature review of therapeutic expectancy effects.","volume":"34","author":"Tambling","year":"2012","journal-title":"Contemp Fam Ther"},{"issue":"1","key":"zoi260379r53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12888-025-06737-z","article-title":"Treatment expectancy and credibility as predictors of concentrated exposure treatment outcomes in patients with difficult-to-treat obsessive-compulsive disorder.","volume":"25","author":"Berg","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"35","key":"zoi260379r54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies.","volume":"16","author":"Savovic","year":"2012","journal-title":"Health Technol Assess"},{"key":"zoi260379r28","volume-title":"International Statistical Classification of Diseases, Tenth Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"zoi260379r31","author":"Guy","year":"1976"},{"key":"zoi260379r44","author":"Furukawa","year":"2016"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849099\/yngwe_2026_oi_260379_1778259670.77729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:30:31Z","timestamp":1778859031000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849099"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.12589","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}